Entropy Technologies LP Invests $3.62 Million in IQVIA Holdings Inc. (NYSE:IQV)

Entropy Technologies LP acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 18,440 shares of the medical research company’s stock, valued at approximately $3,624,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Sanctuary Advisors LLC bought a new stake in IQVIA in the 2nd quarter worth approximately $803,000. Wedmont Private Capital lifted its position in IQVIA by 9.5% in the 3rd quarter. Wedmont Private Capital now owns 2,042 shares of the medical research company’s stock worth $460,000 after buying an additional 178 shares during the last quarter. UMB Bank n.a. lifted its position in IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares during the last quarter. Clarius Group LLC bought a new stake in IQVIA in the third quarter valued at approximately $202,000. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its position in IQVIA by 429.2% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,233 shares of the medical research company’s stock valued at $292,000 after purchasing an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent research reports. UBS Group lowered their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday. Redburn Atlantic began coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday. JPMorgan Chase & Co. decreased their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $252.39.

Insider Transactions at IQVIA

In other news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Down 0.9 %

Shares of IQVIA stock opened at $208.13 on Friday. The company has a market cap of $37.78 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company’s 50 day moving average is $200.67 and its 200 day moving average is $219.54. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.